secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001493152-26-012991
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics pivots to DTC skincare; reports year-end 2025 cash of $7.5M
--------------------------------------------------------------------------------

- Strategic pivot from prescription derm to direct-to-consumer skincare brand Tome; first product launch mid-2026.
- Cash and equivalents $7.5M at Dec 31, 2025 ($3.2M prior year); funded into Q1 2027.
- Raised $15.4M gross in 2025/early 2026 including $4.125M private placement with insider participation.
- R&D expenses fell to $2.9M from $8.2M as STAR-1 acne study completed; SG&A up to $4.8M on marketing.
- Hired Kyra Peckaitis as VP Marketing; withdrew XYNGARI IND despite positive Phase 3 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/0001493152-26-012991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer